Investment Prospectus - UCD-MBA


Dec 5, 2012 (6 years and 7 months ago)


Investment Prospectus


Prepared by:

Kung Chiao


Joseph Wheeler

Javier Zuniga

9885 Towne Centre Drive

San Diego, CA


Phone: 858

Fax: 858

Web Site:

Sector: Healthcare

Industry: Biotechnology

Market Cap: $4.1 Billion (11/13/09)

Sector Market Cap: $1,885.4 Billion (11/13/09)

Industry Market Cap: $225.8 Billion (11/13/09)

Employee headcount: 1
536 (12/28/08)


Illumina was founded in April of 1998 by David Walt, Ph.D., CW Group (Larry Bock), John Stuelpnagel,
D.V.M., Anthony Czarnik, Ph.D., and Mark Chee, Ph.
D. using exclusive Beadarray technology licensed from
Tufts University.

Illumina’s customers include
eading genomic research centers,

, pharmaceutical

clinical research organizations,
and biotechnology



Genotyping services with first contract with GlaxosmithKline


Released SNP genotyping com
mercial system


Released gene expression profiling


Benchtop BeadStation system available for mainstream laboratories and researchers

DASL Assay available, a new approach for generating gene expression profiles from partially
degraded RNA samples


Three genome products: whole
genome expression microarrays, Infinium Assay, whole
expression arrays for mouse


HumanHap300* Genotyping BeadChip, HumanHap550* BeadChip, HumanHap650Y *BeadChip
(*represents 100kx marker on single microarray)

Genotyping and gene expression services


Digital Gene Expression launched

BeadXpress system launched


Infinium BovineSNP50 BeadChip released

Illumina sequences first African human genome



CyVera Corporation

Molecular diagnostics



Gene sequencing technology


Avantome, Inc.

Low end genome analyzer market and diagnostics market


To be the leading provider of integrated solutions that advance
the understanding of genetics and health.

Management Team




President & Chief Executive Officer

Prior to his appointment in 1999 as president and chief executive officer of Illumina, Jay was the president
and chief executive officer of Molecular Dynamics, later acquired by Amersham Pharmacia Biotech

now a part of GE Healthcare. As a co
founder and member of the board of directors for Molecular
Dynamics he led the Company to its initial public offering in 1993. While there, he also helped Molecular
Dynamics develop and launch over 15 major instrum
entation systems, including the first capillary
DNA sequencer.

Jay received a B.A. in economics from Claremont McKenna College and a B.S. and M.S. (summa cum
laude) in industrial engineering from Stanford University.




Senior Vice
President & General Counsel

Christian (Chris) Cabou joined Illumina in May 2006. Chris has worldwide responsibility for all legal and
intellectual property matters and is also Illumina’s code of ethics compliance officer.

Chris received a J.D. from Nort
hwestern University School of Law in addition to a M.E.M. from
Northwestern University. Chris was awarded an M.S.E.E. (equivalent) from the Conservatoire National des
Arts et Métiers and a B.S. (equivalent) from the Lycée Technique d'Etat.





Senior Vice President & General Manager, Diagnostics Business Unit

Greg Heath is responsible for managing Illumina’s emerging diagnostics business, specifically overseeing
the development of diagnostic content for the BeadXpress system, and ultim
ately for the Illumina’s
sequencing platform.

Greg has more than 20 years of experience in the diagnostics field, including launching the first FDA
approved microarray for diagnostic use. Greg joined Illumina from Roche Molecular Systems where he
held a
number of senior executive positions including head of clinical genomics, senior vice president of
global product marketing, senior vice president of global marketing and business development, and most
recently, senior vice president of global business. In

this last role, Greg was responsible for new product
development and global marketing activities for the infectious disease, blood screening, genetics and
oncology portfolios. Greg was also responsible for the PCR licensing, industrial business, and busin
development programs. From 2000

2003, Greg was head of business development and licensing for the
diagnostics division of F. Hoffman La Roche in Basel and led the strategic planning, business development,
and licensing activities of the molecular diagn
ostics, centralized diagnostics, applied science, near patient
testing, and diabetes care business areas. Prior to this, Greg held numerous roles in marketing and
business development with Roche Diagnostics’ U.S. affiliate.

Greg graduated with a B.S. in
psychology from Illinois State University and an M.A. in experimental
psychology from Hollins College. He earned a Ph.D. in experimental psychology from Virginia
Commonwealth University and completed his post
doctoral work in behavioral pharmacology at Mic
State University. Outside of his work at Illumina, Greg has also published more than 25 articles in science
and business and participates in various internal and external leadership programs.



Senior Vice President, Corporate Developme
nt & Chief Financial Officer

Christian Henry joined Illumina in June 2005, and is responsible for worldwide financial operations,
controllership functions, and facilities management.

Christian served previously as chief financial officer for
, a publicly
traded online ticket
provider, which was recently acquired by Major League Baseball Advanced Media, LP. Prior to his career
with, Christian was vice president of finance and corporate controller for Affymetrix, Inc.,
where he overs
aw accounting, planning, SEC and management reporting, treasury, and risk management.
He previously held a similar position at Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.).

Christian earned a B.A in biochemistry and cell biology from th
e University of California and an M.B.A.
from the University of California.



Senior Vice President & General Manager, Life Sciences Business Unit

Joel McComb is responsible for managing all products and services related to the research market,
the BeadArray, VeraCode, and sequencing product lines.

Joel joined Illumina from GE Healthcare where he held a number of executive positions including his most
recent position as president of the interventional medicine business. Responsible for a

$700 million
division of GE Healthcare, the interventional medicine group provided a broad collection of products for
the hospital interventional operating suite and physician's office with applications in cardiology,
neurology, and oncology. Prior to thi
s role, Joel was president of life sciences discovery systems, a $600
million division at GE Healthcare. In this role, Joel had responsibility for product development,
manufacturing, service, global sales and marketing, information systems, quality, busine
ss development,
and program management for molecular biology, genomics, proteomic, and cellular imaging products.
From 2001

2004 Joel was president, chief executive officer, and board member of Innovadyne
Technologies. He was responsible for the strategy a
nd implementation of all operations, beginning with
the startup of Innovadyne through its subsequent sale as a profitable business to Gilson, Inc. Prior to
Innovadyne, Joel held various positions at Beckman Coulter, including roles as general manager of th
primary care diagnostic division and director of corporate business development. As general manager,
Joel was responsible for leading Beckman Coulter's $100 million primary care diagnostics division, which
included the former SmithKline diagnostics busin

Joel received a B.S. in genetics from the University of California, Davis and an M.B.A from the Golden Gate




Senior Vice President, Commercial Operations

Tristan Orpin joined Illumina in December 2002 in the role of vi
ce president of worldwide sales, and in
January 2007 was promoted to senior vice president of commercial operations.

Before joining Illumina, Tristan held positions at Sequenom including vice president of sales and
marketing from August 2001 to November
2002 and director of sales and marketing from September
1999 to August 2001. For more than a decade prior Tristan served in several senior sales and marketing
positions at Bio
Rad Laboratories.

Tristan earned a B.S. in genetics and biochemistry with firs
t class honors from the University of




Senior Vice President & Chief Technology Officer

Mostafa Ronaghi, Ph.D., joined Illumina in August 2008 and is responsible for leading internal research
programs and evaluating new te
chnologies for the Company.

Mostafa is an experienced entrepreneur and was involved in the start
up of four life sciences companies.
In 2007, Mostafa co
founded Avantome, a privately
held sequencing company. Before this, he co
NextBio, a search e
ngine for life science data. In 2001, Mostafa co
founded ParAllele Bioscience, which
was eventually acquired by Affymetrix, Inc., and was involved in the development and commercialization
of highly multiplexed technology for genetic testing. In 1997, he co
founded Pyrosequencing AB, which
was renamed to Biotage in 2003, and led the company to a successful initial public offering in June 2000
on the Stockholm Stock Exchange. Mostafa was a principal investigator at Stanford University from 2002

2008 and focus
ed on the development of novel tools for molecular diagnostic applications. He serves on
the board of directors of Microchip Biotechnologies, NextBio, and Aurora Biofuels.

Mostafa earned his Ph.D. from the Royal Institute of Technology in Sweden. Mostafa
holds more than 20
pending and issued patents and has written more than 50 peer
reviewed publications in journals and

Board Of Directors



Rastetter, Ph.D.


William Rastetter has been an Illumina board of director since November
1998 and non
chairman since January 2005. Bill is currently executive chairman of Biogen Idec, Inc. He served as
chairman and chief executive officer of IDEC Pharmaceuticals Corporation until its 2003 merger with
Biogen, preceded by several other

senior positions at the company. From 1984 to 1986, Bill was director
of corporate Ventures at Genentech, where he had earlier held scientific positions. He held a series of
faculty positions at the Massachusetts Institute of Technology from 1975 to 1982.

Bill has a bachelor of science degree in chemistry from the Massachusetts Institute of Technology, and
received master of art and doctorate degrees in chemistry from Harvard University.




Jay Flatley is president and chief executive officer

of Illumina. Prior to his appointment in 1999, Jay was
the president and chief executive officer of Molecular Dynamics, later acquired by Amersham Pharmacia
Biotech in 1998 and now a part of GE Healthcare. Jay, who was a founder and member of the board of

directors for Molecular Dynamics, led the company to its initial public offering in 1993 and helped the
Company develop and launch over 15 major instrumentation systems, including the world's first capillary
based DNA sequencer.

Prior to joining Molecula
r Dynamics, Jay was vice president of engineering and strategic planning for
Plexus Computers, a manufacturer of high
performance Unix super
microcomputers. Before his career at
Plexus, Jay was executive vice president for Manning Technologies and held var
ious manufacturing
positions while working for the Autolab division of Spectra Physics.

Jay received a bachelor of art degree in economics from Claremont McKenna College (Claremont, CA) and
a bachelor of science and master of science (summa cum laude) in

industrial engineering from Stanford
University (Stanford, CA). Currently, he serves as a member for both the board of directors for Illumina
and GenVault Corporation.



Blaine Bowman is the former president and chief executive officer of Dio
nex Corporation. He joined
Dionex in 1977, and served as president and chief executive officer from 1980 until 2002. From 2002
through 2005, he served as the chairman of Dionex. Before joining Dionex, Blaine was a management
consultant with McKinsey and Co
mpany and a product engineer at Motorola Semiconductor Products
Division. Blaine currently serves as a director on the boards of Dionex Corporation, Molecular Devices
Corporation, and Cell Biosciences Corporation. He is also the lead director for Molecular

Devices and Cell

Blaine holds a bachelor of science in physics from Brigham Young University, and a master of business
administration from Stanford University Graduate School of Business.




Daniel Bradbury has been an Illum
ina board of director since January 2004. Currently, Daniel is president
and chief executive officer of Amylin Pharmaceuticals Inc. in San Diego, CA. At Amylin he has served as
president and chief operating officer since June 2003 and a director since June

2006. Prior to his
promotion in June 2003, he was executive vice president since June 2000. He is a member of the board of
directors of Novacea, PhRMA, BIOCOM, the Keck Graduate Institute’s board of trustees, and the San
Diego Regional Economic Developmen
t Corporation. Daniel is a member of the Royal Pharmaceutical
Society of Great Britain and serves on the UCSD Rady School of Management’s advisory council.

Daniel obtained a bachelor of pharmacy degree from Nottingham University and a diploma in
t studies from Harrow and Ealing Colleges of Higher Education.



Karin Eastham has been an Illumina board of director since August 2004. Karin is currently executive vice
president, chief operating officer, and a member of the board of trustee
s of The Burnham Institute for
Medical Research. She also serves as board of director for Amylin Pharmaceuticals, Tercica, SGX
Pharmaceuticals, and Cyntellect. Prior to joining The Burnham Institute in 2004, Karin was senior vice
president, chief financial

officer, and secretary of Diversa Corporation. She previously held similar
positions with CombiChem, Inc., Cytel Corporation, and Boehringer Mannheim Diagnostics.

Karin received both bachelor of science and master of business administration degrees from
University, and is a certified public accountant.


Goldstein, Ph.D.

Jack Goldstein has been an Illumina board of director since June 2006. Jack was president and chief
operating officer of Chiron Corporation until its acquisition by Novartis i
n April 2006. Before Chiron, he
spent two years as a general partner at Windamere Venture Partners preceded by four years at Applied
Imaging Corporation, first as president and chief executive officer and later as chairman. Jack spent over a
decade at Orth
o Diagnostic Systems, a Johnson & Johnson company, in various executive positions
including four years as president. He was earlier vice president of research and development at a division
of Baxter Healthcare Corporation.

Jack earned a bachelor of art d
egree in biology from Rider University, a master of science degree in
immunology, and doctorate. in microbiology from St. John’s University. He sits on the board of directors
of Orasure Technologies Inc.



Grint, M.D.

Paul Grint is chief medical off
icer and head of development at Kalypsys. He has more than 18 years of
experience in biologics and small molecule drug development, marked by the successful development of
numerous commercial products in the fields of infectious disease, immunology, and on
cology. Prior to
joining Kalypsys, Paul was senior vice president and chief medical officer of Zephyr Sciences Inc. He held
similar positions at Pfizer in La Jolla, CA, IDEC Pharmaceuticals and Schering
Plough. Paul began his
pharmaceutical career at the W
ellcome Research Laboratories in the United Kingdom.

Paul received a medical degree from the University of London, St. Bartholomew's Hospital Medical
College in London. He is a fellow of the Royal College of Pathologists, a member of numerous professional

and medical societies, and the author, or coauthor of over 50 publications. Paul is also a member of the
advisory board of CovX and the advisory council of the Keck Graduate Institute.



Walt, Ph.D.

David Walt, one of Illumina’s co
founders, has been an Illumina board of director and chairman of the
Company’s scientific advisory board since June 1998. He has also been the Robinson Profe
ssor of
Chemistry at Tufts University since September 1995. David has published over 150 papers and holds over
40 patents.

David earned a bachelor of science in chemistry from the University of Michigan and received a doctorate
in chemical biology from th
e State University of New York at Stony Brook.



Roy Whitfield is the former president, chief executive, and chairman of Incyte C
orporation. Roy co
founded Incyte in 1989 and served as its chief executive until 2001 and as chairman of the board from
2001 until 2003. In 1997, Roy was named Northern California Entrepreneur of the Year for life sciences.
From 1984 to 1989, Roy held gen
eral management and business development positions with Technicon
Instruments Corporation, a medical instrumentation company, and its predecessor company, Cooper
Biomedical, Inc., a biopharmaceutical and medical diagnostics company. Prior to his work at Te
Roy spent seven years in the Boston Consulting Group’s international management consulting practice.

Roy earned a bachelor of administration degree in mathematics from Oxford University and a master of
business administration degree from Stanfor
d University Graduate School of Business. He currently serves
as a director of Incyte Corporation, Nektar Therapeutics, Inc., and three privately held biotechnology


Genome Analyzer

The Genome Analyzer IIx offers a unique
combination of 2 x 100 bp read length and >300 million reads
per flow cell with the simplest and fastest workflow. The highest raw accuracy and the largest number of
perfect reads enables a broad range of high
throughput sequencing applications. Power your

and generate highly accurate results in a week with the Genome Analyzer IIx.


iScanSQ is the first system to integrate the high
throughput capability of genotyping and gene expression
microarrays with the flexibly and resolution of n
generation sequencing. With the addition of the SQ
Module, the iScan system now offers a convenient and economical gateway to the power of next
generation sequencing.

The iScan System is a cutting
edge, high
resolution, scanner that supports rapid, s
ensitive, and accurate
imaging of Illumina's array
based genetic analysis products. The system features a high signal
ratio, high sensitivity, an excellent limit of detection, and a broad dynamic range leading to exceptionally
high data quality.

The BeadXpress Reader is ideal for small and high
throughput labs conducting low

to mid
plex molecular
testing studies that need robust, multiplexed
based assays. The Reader employs a dual
color laser
detection system to identify the unique holographic c
ode inscribed in each VeraCode microbead and to
detect the signal intensity associated with each bead

Intellectual Property

Patent portfolio as of February 1, 2009, includes ownership or exclusive licenses to 135 issued patents and
169 pending U.S, paten
ts. Patents related to arrays, assays, oligo synthesis, sequencing technology,
instruments and chemical detection technologies will expire between 2010 and 2026.

Geographic Location

Employee headcount for R&D: 406



Square Feet


San Diego, CA


R&D, Manufacturing, Storage,

Distribution and Administrative

Hayward, CA


R&D, Manufacturing and Administrative



Manufacturing and Administrative

Little Chesterford,


D, Manufacturing and Administrative

Tokyo, Japan


Sales and Administrative



Distribution and Administrative

Melbourne, Australia


Sales and Administrative

Competitive Landscape

Competitors include companies that offer products and services for the sequencing, SNP genotyping, and
gene expression markets. Namely,
Affymetrix, Agilent, Beckman Coulter, Complete Genomics, Fluidigm,

Corp., Life Technologies, Luminex, Pacific Biosc
iences, Roche Diagnostics and Sequenom

are the

main competitors. We anticipate intense competition from these companies as they develop new
or improved products. We may also face competition from new companies as they enter the market with
new te
chnologies. It is also worth noting that some competitors have greater financial and personnel
resources, broader product lines, a more established customer base

and more experience in research and
development. Furthermore, it is possible that existing c
ustomers or partners in the life sciences or
pharmaceutical areas to enter the market by developing competing products. For these reasons, it is
imperative to that our products maintain a competitive advantage in the areas of throughput, cost, and

The race to commercialize full genome sequencing for personalized healthcare is one of the long term
goals, but competitors such as
Life Technologies
Pacific Biosciences
, and
Complete Genomics

are also
pursuing the same objective. With affordable
full genome sequencing and a better understanding of
correlation between genetic variants and disease, the healthcare industry will be evolutionized.